Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li>The All India Institute of Medical Sciences (AIIMS) and the Indian Council of Medical Research (ICMR) have issued new guidelines for the treatment of patients with COVID-19.</li><li>Patients with moderate COVID-19, those with respiratory distress, should be put under hospital care until their oxygen saturation levels are at reasonable levels.</li><li>Here is the full list of guidelines by AIIMS and ICMR for moderate COVID-19 patients — simplified. </li></ul>The All India Institute of Medical Science (AIIMS) and the Indian Council of Medical Research (ICMR) have jointly issued new guidelines for the treatment of COVID-19 patients depending on the severity of a case — mild, moderate, or severe. And, in the case of moderate infections, India’s apex hospital has recommended that the concerned patient should be admitted into a hospital ward. <cmsannotation type="cmsannotation" annotationid="How to identify a patient with moderate COVID-19 infection?" comment="subhead" text="How to identify a patient with moderate COVID-19 infection?">How to identify a patient with moderate COVID-19 infection?</cmsannotation> According to AIIMS, a patient is classified as having a moderate case of COVID-19 if their respiratory rate is more than 24 breaths per minute and their SpO2 levels — level of oxygen saturation — are between 90% to 93% on room air. This means the patient is likely to be experiencing breathlessness and needs to be in hospital care. <cmsannotation type="cmsannotation" annotationid="Recommendations to help with oxygen support" comment="subhead" text="Recommendations to help with oxygen support">Recommendations to help with oxygen support</cmsannotation> The targeted levels of oxygen saturation, or SpO2, should be between 92% to 96%. For patients with chronic obstructive pulmonary disease (COPD), the recommended SpO2 level is between 88% to 92%. AIIMS and ICMR recommend a non-rebreathing face mask for oxygenation. All patients that require supplemental oxygen therapy should also be awake proning. This is when healthcare workers have patients lie on their stomachs to help with the oxygenation process. According to the guidelines, a patient’s position shoud be changed approximately every two hours. <cmsannotation type="cmsannotation" annotationid="Anti-inflammatory or immunomodulatory therapy" comment="subhead" text="Anti-inflammatory or immunomodulatory therapy">Anti-inflammatory or immunomodulatory therapy</cmsannotation> Immunomodulatory therapy treats diseases targeting the immune system and anti-inflammatory therapy reduces internal swelling. AIIMS and ICMR recommend giving 0.5 to 1 mg/kg of methylprednisolone, which is usually used to treat <a href="https://medlineplus.gov/druginfo/meds/a601157.html">severe allergic reactions</a>, divided over two doses — or an equivalent dose of dexamethasone, also used to treat severe allergic reactions — for five to 10 days as injections. Patients can be switched over to oral medication once they show improvement or are stable. <cmsannotation type="cmsannotation" annotationid="Anticoagulation" comment="subhead" text="Anticoagulation">Anticoagulation</cmsannotation> Anticoagulants, also known as blood thinners, are used to prevent blood clots in COVID-19 patients. The guidelines recommend that moderate COVID-19 cases should be given the conventional dose of prophylactic unfractionated heparin, normally used to treat deep vein thrombosis prophylaxis — blood clots, usually in the legs. They can also be given Low Molecular Weight Heparin (LMWH), like 0.5 mg/kg of enoxaparin every day. But anticoagulants should only be used for patients with no contraindication or high risk of bleeding. <cmsannotation type="cmsannotation" annotationid="Things to monitor with moderate COVID-19 patients" comment="subhead" text="Things to monitor with moderate COVID-19 patients">Things to monitor with moderate COVID-19 patients</cmsannotation> <ol><li>Work of breathing — the number of breaths per minute</li><li>Hemodynamic instability — changes in the flow of blood</li><li>Change in oxygen requirement — or oxygen saturation</li><li>Regular X-Rays, HRCT chest scans should only be done if the patient’s condition worsens</li><li>CRP and D-dimer tests to be conducted every 48 hours to 72 hours.</li></ol>SEE ALSO: <a href="https://www.businessinsider.in/science/health/news/clinical-guidance-and-treatment-for-severe-covid-19-patient-as-per-aiims/icmr/articleshow/82210693.cms">Here’s the clinical guidance one needs to follow for a 'severe' COVID-19 patient as per AIIMS/ICMR</a> <a href="https://www.businessinsider.in/science/health/news/mild-covid-19-symptoms-and-treatment-as-per-aiims-new-guidelines/articleshow/82210494.cms">What you can do if you have 'mild' COVID-19 symptoms, according to new AIIMS/ICMR guidelines</a>

Simplified: AIIMS, ICMR new guidelines for treatment of patients with ‘moderate’ case of COVID-19

New Delhi, <keyword id="40458" type="COMPANY" weightage="20" keywordseo="AIIMS">AIIMS</keyword> Director <keyword id="209402" type="PERSON" weightage="20" keywordseo="Randeep-Guleria">Randeep Guleria</keyword> on Monday allayed apprehensions about the <keyword id="8901548" type="UNKNOWN" weightage="20" keywordseo="coronavirus-vaccines">coronavirus vaccines</keyword> and assured that the side-effects will not result in death of the beneficiary. The nationwide Covid vaccination drive had commenced on January 16 and a total of 447 adverse events following immunisation (AEFI) were reported during the first two days, with most of them being minor along with three cases of hospitalisation. "Even if a person takes Crocin or Paracetamol, they may develop allergic reactions. There is nothing to worry about. There is no side-effect which would result in death," Dr Guleria said. He added, "Main side-effects are body ache, fever, pain at injection site which subside in 1-2 days and take place in less than 10 per cent of people. If the side-effects are severe, there could be skin rashes, nausea, difficulty in breathing." The AIIMS Director said that people must come forth to get vaccinated if they want <keyword id="3658" type="LOCATION" weightage="20" keywordseo="India">India</keyword> to come out of the Covid-19 pandemic, decrease the mortality rate, bring the economy back on track and reopen schools. On January 16, moments after Prime Minister Narendra Modi launched the vaccination drive across the country, the jab was administered to the AIIMS chief on live telecast. Dr Guleria was the third person to take the shot in the institute. "I have no side-effects. I am feeling perfectly alright," he told the media, two days after taking the jab, in a bid to allay fears and apprehensions about the safety of the coronavirus vaccines. The rollout of Oxford's 'Covishield' vaccine, manufactured by <keyword id="95879" type="COMPANY" weightage="20" keywordseo="Serum-Institute-of-India">Serum Institute of India</keyword>, and <keyword id="149108" type="PERSON" weightage="20" keywordseo="Bharat-Biotech">Bharat Biotech</keyword>'s '<keyword id="9485939" type="PERSON" weightage="20" keywordseo="covaxin">Covaxin</keyword>' began in the country amid apprehensions about the safety of the latter. Covaxin is currently undergoing late-stage clinical trials which are crucial to determining the efficacy of the shot. 'Covaxin' has been in the spotlight ever since it received the green signal from the drug regulator for restricted emergency use. The approval without adequate efficacy data drew flak from public health advocacy groups, researchers, scientists and activists. Meanwhile, as many as 2,24,311 beneficiaries have received doses of Covid-19 vaccines in the last two days. Only 17,072 beneficiaries were vaccinated in six states on Day 2. SEE ALSO: <a href="https://www.businessinsider.in/stock-market/news/how-rakesh-jhunjhunwala-backed-nazara-technologies-is-preparing-for-its-big-ipo-debut/articleshow/80321946.cms">The startup behind Chhota Bheem, Motu Patlu and Shikari Shambhu is back with an IPO plan ⁠⁠— after a series of acquisitions and fundraisings</a> <a href="https://www.businessinsider.in/stock-market/news/heres-what-analysts-have-to-say-about-the-4634-crore-indian-railway-finance-corporation-irfc-ipo/articleshow/80323479.cms?upcache=2">The ₹4,600 crore IPO from IRFC is ‘attractive,’ and the best thing about the borrowing arm for Indian Railways is the assured margin</a> <a href="https://www.businessinsider.in/stock-market/news/how-to-apply-for-indian-railway-finance-corporation-irfc-ipo/articleshow/80327303.cms">How to apply for IRFC IPO? Check the details and online application process here</a> <a href="https://www.businessinsider.in/business/startups/news/cure-fit-strengthens-its-us-offering-by-acquiring-digital-trainer-and-workout-app-onyx/articleshow/80326857.cms">Cure.fit strengthens its US offering by acquiring digital trainer and workout app Onyx</a>

'Vaccine won't kill you': AIIMS Director allays fears

Indian vaccines offer lot of hope, due to various factors including a good safety signal, display of immunogenicity and capability of using the current storage infrastructure, said AIIMS Director Randeep Guleria in an exclusive interview with IANS. Recently, drug company <keyword id="44612" type="CITY" weightage="20" keywordseo="Pfizer">Pfizer</keyword> announced that its vaccine candidate for Covid-19 is more than 90 per cent effective at preventing infection. This was welcomed as a major step in the fight against the virus, which has unleashed havoc on the global economy. Guleria added that the Indian Covid-19 vaccine has a huge advantage over the Pfizer vaccine, which is required to be kept at a much lower temperature, and hence, cold storage for other vaccines can be used for the Indian vaccine too. Q: We have not seen any major issue with Indian vaccines at the trials stage, are you satisfied with progress made so far? A: Indian vaccines have a lot of hope and there are two or three reasons for that, one is that their safety signal is very good and immunogenicity is also being shown, and one is now looking at the results of Phase-3 trials, which will take some time, but I am hopeful we will have good amount of data because multi-centric studies is being done. We quickly will be able to generate some interim analysis to show in Phase-3 trials this vaccine can give good efficacy. Q: Drug company Pfizer announced that its vaccine candidate for Covid-19 is more than 90 per cent effective at preventing infection. Are Indian vaccines on a better footing than Pfizer? A: What Pfizer has got is something very encouraging for other vaccines researchers also, because that shows there is a potential of good immunity by the vaccines. Therefore, other vaccines should also do well. Therefore, it is a big news for all vaccine developers. We can hope for a 90 per cent efficacy. The advantage for the Indian vaccine is that it is required to be kept at a much lower temperature. The Pfizer vaccine currently have to be kept at minus 70 degrees Celsius, therefore it will be very difficult to vaccinate people in lower- and middle-income countries. Because having a vaccine stored and transported at minus 70 degree Celsius not only needs huge investment but also needs huge planning, because most vaccines are not kept at that low temperatures. The Indian vaccines are going to be kept at a temperature of minus 20 degrees Celsius and this is available for most vaccines. As most vaccines a have cold storage facility, these can be used for this vaccine also. Therefore, the investment is not much. If we were to use a vaccine which require storage at minus 70 degrees Celsius, then one would require whole new cold chain development. I do not see that happening in lot of countries. Q: Is 90 per cent efficacy is being aimed at by Indian companies developing vaccine against Covid-19? A: We would like to have as much efficacy as one can. The WHO says if any vaccine has more than 50 per cent efficacy, it is good enough. We would definitely like to have an efficacy of 80-90 per cent. So, let us hope that is what we are able to achieve. SEE ALSO: <a href="https://www.businessinsider.in/politics/india/news/checkout-here-bihar-assembly-election-2020-results-and-updates-online/articleshow/79142084.cms">Bihar Election Results 2020: Final tally puts NDA in the majority with 125 seats as RJD remains the single largest party</a> <a href="https://www.businessinsider.in/india/news/psu-bank-employees-wage-revision-finalised-after-three-years-of-waiting-only-a-1500-increase-in-salary-for-officers/articleshow/79166497.cms">PSU bank employees wage revision finalised after three years of waiting — only a ₹1,500 increase in salary for officers</a> <a href="https://www.businessinsider.in/tech/apps/news/instagram-down-users-complain-of-frozen-timelines-and-likes/articleshow/79146012.cms">Instagram down for nearly 24 hours— users continue to complain about frozen timelines and likes</a>

Indian COVID vaccines can survive in warmer temperatures than Pfizer's, says AIIMS Director

<keyword id="149108" type="PERSON" weightage="20" keywordseo="Bharat-Biotech">Bharat Biotech</keyword>'s COVID-19 vaccine <keyword id="9485939" type="PERSON" weightage="20" keywordseo="covaxin">Covaxin</keyword> was on Tuesday recommended by an expert panel for <keyword id="6393270" type="UNKNOWN" weightage="20" keywordseo="phase">phase</keyword> II/III <keyword id="122283" type="PERSON" weightage="20" keywordseo="Clinical-trial">clinical trial</keyword> on those aged between two to 18 years, official sources said. The trial will take place in 525 subjects at various sites, including <keyword id="40458" type="COMPANY" weightage="20" keywordseo="AIIMS">AIIMS</keyword>, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur. The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (<keyword id="6375144" type="COMPANY" weightage="20" keywordseo="cdsco">CDSCO</keyword>) on Tuesday deliberated upon Hyderabad-based Bharat Biotech's application seeking permission to conduct phase II/III clinical trials to evaluate the safety, reactogenicity and immunogenicity of Covaxin jabs in children aged 2 to 18 years. "After detailed deliberation, the committee recommended for conduct of proposed phase II/III clinical trial of whole virion inactivated coronavirus vaccine in the 2 to 18 years age group subject to the condition that the firm should submit the interim safety data of phase II clinical trial along with DSMB recommendations to the CDSCO before proceeding to phase III part of the study," a source said. Earlier the proposal was deliberated in the SEC meeting dated February 24 and the firm was asked to submit a revised clinical trial protocol. Covaxin, indigenously developed by Bharat Biotech in collaboration with the <keyword id="3658" type="LOCATION" weightage="20" keywordseo="India">India</keyword>n Council of Medical Research (ICMR), is being used in adults in India's ongoing COVID-19 vaccination drive. SEE ALSO: <a href="https://www.businessinsider.in/tech/apps/news/whatsapp-responds-to-privacy-criticism-by-alleging-other-apps-like-zomato-ola-aarogya-setu-zoom-google-and-other-apps/articleshow/82570897.cms">WhatsApp responds to privacy criticism by alleging that other apps and tech companies also show disdain for user privacy</a> <a href="https://www.businessinsider.in/business/telecom/news/vodafone-idea-adds-subscribers-for-the-first-time-in-15-months/articleshow/82568343.cms">Vodafone Idea shares up by 10% as it adds subscribers for the first time in 15 months – Airtel, Reliance Jio expand their user base</a>

You Searched For "AIIMS coronavirus" and got 4 results

Simplified: AIIMS, ICMR new guidelines for treatment of patients with ‘moderate’ case of COVID-19

Prabhjote Gill

'Vaccine won't kill you': AIIMS Director allays fears

IANS

Indian COVID vaccines can survive in warmer temperatures than Pfizer's, says AIIMS Director

IANS

Bharat Biotech's COVAXIN reportedly recommended by expert panel for phase 2 and 3 clinical trials on 2-18 year-olds

PTI

Popular Keywords

Buying Guides